Análisis de la acción Vertex Pharmaceuticals Inc (VRTX)VRTXVertex Pharmaceuticals Inc

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Vertex Pharmaceuticals is a good buy right now due to its strong market position and growth potential. The current price is $541.69, with a forward P/E ratio of 28.99, indicating reasonable valuation relative to future earnings. Additionally, the company has a gross margin of 85.33%, which demonstrates its pricing power and profitability. However, insider selling has increased by 753.33% over the last month, which is a notable risk.

27 analysts cover VRTX: 22 rate it Buy, 5 Hold and 0 Sell. The average price target is 515.88.